The HALO™ Breast Pap Test has been FDA approved for the collection of nipple aspirate fluid for cytological evaluation. The collected fluid can be used in the determination and/or differentiation of normal versus pre-malignant versus malignant cells.

Incorporating the HALO system into routine practice will enable physicians and patients to monitor cellular changes within breast ducts earlier, before they develop into larger, potentially cancerous lesions that may much later be detected by conventional breast cancer screening modalities like mammography or manual breast examination.

The HALO System is a simple, reliable method for NAF collection. NAF analysis is an objective assessment of a patient's breast health and can detect early warning signs of ductal cellular changes. Regular assessment and tracking of cellular changes in the milk ducts, where most breast cancer begins, enables clinicians and patients to take control of breast health.

The HALO™ Breast Pap Test is the only fully automated, noninvasive NAF collection system specifically designed for use in a busy primary care setting.

The HALO System provides important benefits to clinicians and patients:

For the clinician:

• Routine NAF screening
• Objective assessment for documentation
• Consistent and reproducible
• Fully automated
• User friendly - requires no specialized training or certification
• Performed by office staff
• Easily transported from room to room
• Makes financial sense

For patients:

• Noninvasive
• Simple 5-minute procedure
• Can be performed during annual check up
• Well tolerated by most patients
• Safe, with no side effects
• Inexpensive

Like the cervical Pap test, HALO is not a diagnostic test and it cannot be used to exclude breast cancer. Patients should continue to undergo other clinical breast screening procedures (mammography, clinical breast examination, self breast examination) as determined by and with their physicians.

Click to view
HALO Brochure
HALO system and components

Back to top